Acris Antibodies

acris-antibodies.com

Acris GmbH was founded 1998 as a spinoff of DPC Biermann GmbH, the German subsidiary of Diagnostic Products Corp., Los Angeles. Acris took over responsibility for marketing the DPC Biermann research products, mostly antibodies. From the very beginning it was our mission to serve the research community with high quality research products. It was our strategy to develop a platform for thousands of high quality antibodies in one easy to search online database.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BICYCLE AND GENENTECH FORGE IMMUNO-ONCOLOGY COLLABORATION WORTH UP TO $1.7 BILLION

BioSpace | February 25, 2020

news image

Shares of U.K.-based Bicycle Therapeutics are climbing this morning after the company announced it entered into a strategic immuno-oncology collaboration with Genentech to discover, develop and commercialize novel Bicycle-based immuno-oncology therapies. The collaboration has a value of up to $1.7 billion if all milestones are hit. Under terms of the agreement, Bicycle will receive an upfront payment of $30 million to focus its proprietary bicyclic peptides platform on a wide range of immuno-onc...

Read More

Medical

ARUNA BIO ADVANCES THERAPEUTIC DEVELOPMENT FOR TRAUMATIC BRAIN INJURY

Aruna Bio | June 01, 2022

news image

Aruna Bio, Inc., a leader in the development of neural exosome based therapeutics for the treatment of neurodegenerative diseases, today announced that it has received funding from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health of Health to advance AB126™, a multimodal neuroprotective and regenerative neural stem cell extracellular vesicle (NSC EV) product, to treat Traumatic Brain Injury (TBI). The succ...

Read More

ENZO BIOCHEM’S FULL SERVICE CLINICAL LABORATORY TO LAUNCH CORONAVIRUS (COVID-19) TESTING SERVICES NEXT WEEK

Biotechnology news | March 06, 2020

news image

Enzo Biochem, Inc. (NYSE:ENZ) today announced that its wholly owned subsidiary, Enzo Clinical Labs, Inc., will begin accepting specimens for novel Coronavirus (COVID-19) testing next week. COVID-19 is a contagious virus that is believed to spread by person-to-person transmission and may have serious health consequences. The virus has infected more than 93,000 people globally including recent detections in the United States. Enzo has many years of experience processing specimens for the detection...

Read More

AMUNIX RAISES $73 MILLION IN SERIES A FINANCING LED BY OMEGA FUNDS

BioSpace | March 04, 2020

news image

Amunix Pharmaceuticals Inc. (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers, today announced the successful completion of an oversubscribed $73 million Series A financing. Boston-based Omega Funds led the financing, with participation from existing investor Frazier Healthcare Partners and new investors Longitude Capital, Redmile Group, Polaris Partners, C...

Read More
news image

BICYCLE AND GENENTECH FORGE IMMUNO-ONCOLOGY COLLABORATION WORTH UP TO $1.7 BILLION

BioSpace | February 25, 2020

Shares of U.K.-based Bicycle Therapeutics are climbing this morning after the company announced it entered into a strategic immuno-oncology collaboration with Genentech to discover, develop and commercialize novel Bicycle-based immuno-oncology therapies. The collaboration has a value of up to $1.7 billion if all milestones are hit. Under terms of the agreement, Bicycle will receive an upfront payment of $30 million to focus its proprietary bicyclic peptides platform on a wide range of immuno-onc...

Read More
news image

Medical

ARUNA BIO ADVANCES THERAPEUTIC DEVELOPMENT FOR TRAUMATIC BRAIN INJURY

Aruna Bio | June 01, 2022

Aruna Bio, Inc., a leader in the development of neural exosome based therapeutics for the treatment of neurodegenerative diseases, today announced that it has received funding from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health of Health to advance AB126™, a multimodal neuroprotective and regenerative neural stem cell extracellular vesicle (NSC EV) product, to treat Traumatic Brain Injury (TBI). The succ...

Read More
news image

ENZO BIOCHEM’S FULL SERVICE CLINICAL LABORATORY TO LAUNCH CORONAVIRUS (COVID-19) TESTING SERVICES NEXT WEEK

Biotechnology news | March 06, 2020

Enzo Biochem, Inc. (NYSE:ENZ) today announced that its wholly owned subsidiary, Enzo Clinical Labs, Inc., will begin accepting specimens for novel Coronavirus (COVID-19) testing next week. COVID-19 is a contagious virus that is believed to spread by person-to-person transmission and may have serious health consequences. The virus has infected more than 93,000 people globally including recent detections in the United States. Enzo has many years of experience processing specimens for the detection...

Read More
news image

AMUNIX RAISES $73 MILLION IN SERIES A FINANCING LED BY OMEGA FUNDS

BioSpace | March 04, 2020

Amunix Pharmaceuticals Inc. (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers, today announced the successful completion of an oversubscribed $73 million Series A financing. Boston-based Omega Funds led the financing, with participation from existing investor Frazier Healthcare Partners and new investors Longitude Capital, Redmile Group, Polaris Partners, C...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us